Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precision Biosciences Inc

5.33
-0.1700-3.09%
Post-market: 5.330.00000.00%17:06 EDT
Volume:69.47K
Turnover:373.55K
Market Cap:55.87M
PE:5.13
High:5.68
Open:5.49
Low:5.16
Close:5.50
Loading ...

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

Zacks
·
16 Apr

Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV

MT Newswires Live
·
15 Apr

Precision BioSciences receives FDA fast track designation for PBGENE-HBV

TIPRANKS
·
15 Apr

Precision BioSciences Receives U.S. FDA Fast Track Designation for Pbgene-Hbv, a First-in-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

THOMSON REUTERS
·
15 Apr

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Business Wire
·
15 Apr

TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Zacks
·
10 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
26 Mar

Precision BioSciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Mar

BRIEF-Precision Biosciences Reports Fourth Quarter And FY 2024 Results

Reuters
·
26 Mar

Precision BioSciences: Q4 Earnings Snapshot

Associated Press Finance
·
26 Mar

As Of December 31, 2024, Precision BioSciences Had Approximately $108.5M In Cash, Cash Equivalents, And Restricted Cash, With Expected Cash Runway Into The Second Half Of 2026

Benzinga
·
26 Mar

Precision BioSciences Q4 2024 GAAP EPS $(2.22) Misses $(1.96) Estimate, Sales $638.00K May Not Be Comparable To $4.28M Estimate

Benzinga
·
26 Mar

Precision BioSciences Inc - Cash Runway Expected to Last Into Second Half of 2026

THOMSON REUTERS
·
26 Mar

Precision BioSciences, Inc. Q4 Basic EPS USD -2.22

THOMSON REUTERS
·
26 Mar

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Business Wire
·
26 Mar

Precision BioSciences Inc expected to post a loss of $1.96 a share - Earnings Preview

Reuters
·
24 Mar

Precision BioSciences Inc expected to post a loss of $1.96 a share - Earnings Preview

Reuters
·
21 Mar

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

THOMSON REUTERS
·
21 Mar